Profile of:
Abhijeet Danve
Abhijeet Danve is Associate Professor of Medicine and Director of Spondyloarthritis Program at Yale University School of Medicine, New Haven CT. He is a clinician and researcher with particular interest in improving the early diagnosis of axSpA using screening and referral strategies, translational research and improving awareness about axSpA among non-rheumatology physicians. He is recipient of Jane Bruckel Early Career Investigator Award from Spondylitis Association of America (SAA) and Distinguished Fellow award from American College of Rheumatology. His work has been supported by Spondyloarthritis Research and Treatment Network, SAA and industry.
Full name: Abhijeet Danve
Current country: United States
Membership level: Full
Type of membership: Member
Number of publications: 16
Early diagnosis of axial spondyloarthritis among patients with chronic back pain using a clinical screening tool and referral strategy (2025)
https://pubmed.ncbi.nlm.nih.gov/40901640/
Psychosocial burden of axial spondyloarthritis and impact of different disease domains: a systematic literature review (2025)
https://pubmed.ncbi.nlm.nih.gov/40584930/
Knowledge, Awareness, and Attitudes Regarding Axial Spondyloarthritis Among Nonrheumatology Physicians in the United States (2025)
https://pubmed.ncbi.nlm.nih.gov/40041999/
Klippel-Feil Syndrome in a Patient Referred for Axial Spondyloarthritis (2025)
https://pubmed.ncbi.nlm.nih.gov/41392715/
An update on the management of axial spondyloarthritis for sports medicine professionals (2024)
https://pubmed.ncbi.nlm.nih.gov/39375817/
Ixekizumab Treatment Patterns and Health Care Resource Utilization Among Patients with Axial Spondyloarthritis: A Retrospective United States Claims Database Study (2024)
https://pubmed.ncbi.nlm.nih.gov/39162898/
How to Monitor Disease Activity of Axial Spondyloarthritis in Clinical Practice (2024)
https://pubmed.ncbi.nlm.nih.gov/38372873/
Treatment of axial spondyloarthritis: an update (2022)
https://pubmed.ncbi.nlm.nih.gov/35273385/
Efficacy and Safety of Intravenous Golimumab in Patients With Ankylosing Spondylitis and Complete Spinal Ankylosis: Results Through Week 52 of the GO-ALIVE Study (2022)
https://pubmed.ncbi.nlm.nih.gov/35649533/
Assessing rheumatologists’ attitudes and utilization of classification criteria for ankylosing spondylitis and axial spondyloarthritis: a global effort (2021)
https://pubmed.ncbi.nlm.nih.gov/32797363/
The effect of intravenous golimumab on health-related quality of life and work productivity in adult patients with active ankylosing spondylitis: results of the phase 3 GO-ALIVE trial (2021)
https://pubmed.ncbi.nlm.nih.gov/32926247/
Recognizing Axial Spondyloarthritis: A Guide for Primary Care (2020)
https://pubmed.ncbi.nlm.nih.gov/32736944/
Axial spondyloarthritis in the USA: diagnostic challenges and missed opportunities (2019)
https://pubmed.ncbi.nlm.nih.gov/30588555/
Thoracic Manifestations of Ankylosing Spondylitis, Inflammatory Bowel Disease, and Relapsing Polychondritis (2019)
https://pubmed.ncbi.nlm.nih.gov/31376894/
Routine Assessment of Patient Index Data 3 score (RAPID3) correlates well with Bath Ankylosing Spondylitis Disease Activity index (BASDAI) in the assessment of disease activity and monitoring progression of axial spondyloarthritis (2015)
https://pubmed.ncbi.nlm.nih.gov/25421013/
Screening and referral for axial spondyloarthritis–need of the hour (2015)
https://pubmed.ncbi.nlm.nih.gov/25946983/